Indapamide Tablets 1mg (Natrix® / ナトリックス錠1)

JPY ¥1,900

Japanese sustained-release non-thiazide antihypertensive agent (Indapamide 1mg). Oral tablet for the treatment of essential hypertension. 100 tablets [10 tablets (PTP) x 10]. Mfd. by Kyoto Pharmaceutical Industries, Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥1,748
10 - 19 12% JPY ¥1,672
20 + 18% JPY ¥1,558
SKU: NAT-1-TAB Category:

Description

Product Overview / 商品概要

Natrix Tablets 1mg (ナトリックス錠1)
Generic: Indapamide / インダパミド
Therapeutic Category: Sustained-release non-thiazide antihypertensive agent / 持続型非チアジド系降圧剤
Manufactured by: Kyoto Pharmaceutical Industries, Ltd. / 京都薬品工業株式会社

Composition & Specification / 組成・規格

Active Ingredient: Indapamide (JP) 1mg per tablet / 1錠中日局インダパミド1mg
Additives: Lactose hydrate, Corn starch, Croscarmellose sodium, Hypromellose, Acacia powder, Talc, Magnesium stearate, Polyvinyl alcohol (partially saponified), Titanium oxide, Macrogol 4000, Soybean lecithin / 乳糖水和物、トウモロコシデンプン、クロスカルメロースナトリウム、ヒプロメロース、アラビアゴム末、タルク、ステアリン酸マグネシウム、ポリビニルアルコール(部分けん化物)、酸化チタン、マクロゴール4000、大豆レシチン
Appearance: White to off-white, scored film-coated tablet; major axis approx. 7.7mm, minor axis approx. 6.2mm; identification code: KYO251
外観: 白色〜帯黄白色の割線入りフィルムコーティング錠、長径 約7.7mm、短径 約6.2mm、識別コード: KYO251

Indications / 効能効果

EN: Essential hypertension
JA: 本態性高血圧症

Dosage and Administration / 用法用量

EN: The usual adult dose is 2mg of indapamide once daily administered orally after breakfast. The dose may be adjusted according to age and symptoms, but treatment should be initiated at a low dose and increased gradually.
JA: インダパミドとして、通常成人1日1回2mgを朝食後経口投与する。なお、年齢、症状により適宜増減する。ただし、少量から投与を開始して徐々に増量すること。

Contraindications / 禁忌

EN: Patients with anuria; patients with acute renal failure; patients with apparent decrease in serum sodium or potassium; patients with a history of hypersensitivity to thiazides or related compounds (sulfonamide derivatives); patients receiving desmopressin acetate hydrate (for nocturnal polyuria-related nocturia in males)
JA: 無尿の患者、急性腎不全の患者、体液中のナトリウム・カリウムが明らかに減少している患者、チアジド系薬剤又はその類似化合物(スルフォンアミド誘導体)に対して過敏症の既往歴のある患者、デスモプレシン酢酸塩水和物(男性における夜間多尿による夜間頻尿)を投与中の患者

Regulatory Information / 規制情報

Approval No.: 21400AMZ00038
Sales Started: February 1985 / 1985年2月
Classification Code: 872149
Storage: Store at room temperature. After opening the aluminum pouch, store away from moisture. / 室温保存(アルミピロー開封後は湿気を避けて保存すること)
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets [10 tablets (PTP) x 10] / 100錠[10錠(PTP)×10]
Other Available Packages (by special order): 100 tablets [10 tablets (PTP) x 10], 500 tablets [10 tablets (PTP) x 50], 1,000 tablets [10 tablets (PTP) x 100], 1,000 tablets [bottle, bulk, with desiccant]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Indapamide Tablets 1mg (Natrix® / ナトリックス錠1)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Indapamide Tablets 1mg (Natrix®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.